The positions of Hillhouse, Gao Yi and Jinglin have been exposed since the third quarter, and the concept stocks of medicine and security are on the list.
Reporter | Liu Zenglu
After the National Day holiday, the three-quarter report of listed A shares officially "started", and the position path of institutional investors in the third quarter gradually surfaced, such as the three-quarter report just released.Dahua sharesGao Yi assets and Jinglin assets, two well-known private equity companies, appeared in the top ten shareholders.KelleinAlthough the official quarterly report has not yet met with investors, according to the fixed increase announcement issued on October 12, Hillhouse Capital invested 1 billion yuan in it and became its sixth largest shareholder.
Zhang Lei sold 1 billion yuan to increase his holdings of Kellein.
On the evening of October 12, pharmaceutical leader Kailiying released the "report on the issuance of non-public shares and the listing notice". This time, a total of 10.1778 million shares were issued, raising a total of 2.311 billion yuan. Hillhouse Capital has become the institution with the largest number of additional shares with 4.4053 million shares, with an allocation amount of about 1 billion yuan.
As early as the evening of February 16 this year, after the new refinancing rules of the CSRC were issued, Kellein immediately launched a fixed increase of 2.3 billion yuan and announced that it would be fully subscribed by Hillhouse Capital. The news once aroused great concern in the market, and the share price also rose strongly the day after the announcement. Since then, Kellein's share price has risen all the way up, up more than 70 per cent so far.
On the evening of July 22, Kellein substantially revised its original increase plan, changing the target of a non-public offering from Hillhouse Capital to no more than 35 specific investors; the offering price was revised to no less than 80% of the average stock trading price for the 20 trading days before the announcement of the resolution of the 33rd meeting of the company's third board of directors. After this adjustment, Kellein finally determined that the non-public offering price was raised to 227 yuan per share by bidding. The sales restriction period has been adjusted from 18 months to 6 months.
Due to the adjustment of the fixed increase plan, Hillhouse Capital's plan to subscribe for Kelliying's additional shares as a strategic investor has been shelved, but judging from the announcement issued by Kellein on the evening of October 12, Hillhouse Capital is still the institution with the largest number of shares allocated this time. If you take the Gloria British share price of 280.73 yuan in midday trading on October 13, compared with the fixed increase price of 227 yuan, the capital invested by Hillhouse Capital is about 237 million yuan.
Hillhouse loves the pharmaceutical sector, Gao Yi and Jing Lin appear in Dahua shares.
The A-share quarterly report is made by the main board company of Shanghai Stock Exchange.Jianyou sharesAnd Shenzhen small and medium-sized Board CompanyXingwang YudaIt officially kicked off on October 10, and as of October 13, a total of 11 companies had completed the disclosure of three quarterly reports. With the disclosure of three quarterly reports by listed companies, the positions of some institutional investors have also surfaced.
On October 13, Dahua shares announced three quarterly results and the top ten shareholders, among which Gao Yilinshan No. 1 Yuanwang Fund and Jinglin Global Fund two well-known 10 billion private equity emerged. After Xinjin became a major shareholder of Dahua shares in the second quarter, Feng Liu continued to increase his holdings in the third quarter, with 138 million shares at the end of the third quarter increasing by 52.9999 million shares compared with 85.0001 million shares at the end of the second quarter, and the ranking of shareholders was also promoted from the fourth largest shareholder at the end of the second quarter to the third largest shareholder at the end of the third quarter. Compared with Feng Liu's increase, Jinglin Global Fund reduced its stake in Dahua during the third quarter, to 30.6174 million shares from 30.8119 million at the end of the previous quarter.
According to the pre-disclosure schedule of the three-quarter report, Kelleying's three-quarter report is scheduled for October 24, but judging from the announcement of the result of the increase, Hillhouse Capital has become the company's sixth largest shareholder because of its 4.4053 million shares. Although changes in Hillhouse Capital's shareholdings in other companies during the third quarter have not been made public, combined with previous data, it is still clear that there is no doubt that Zhang Lei has a preference for listed companies in the medical field. Four of the six companies it held at the end of the second quarter belonged to the medical and biological sector, respectively in the medical services sector.Tigermed、Eyre ophthalmology、Golden domain medicineAnd the field of medical devicesKailitai。
As one of the top investment institutions in the world, Hillhouse entered the field of medicine, health care and big health around 2012, and it has invested heavily in a number of tracks. For example, in the field of innovative drugs, its investment exceeds 20 billion yuan, and Baiji has been distributed.Heng RuiThe four major pharmaceutical companies, Junshi and Cinda, have successively invested in the field of medical devices.Peijia Medical treatment和Qiming Medical treatment, fixed increaseMinimally invasive medical treatmentIn the field of pharmaceutical R & D and production outsourcing services, it has invested heavily in domestic leaders in the field of CDMO and clinical CRO, such as Kailiying and Tigermed. Zhang Lei said that investment in biomedicine should adhere to the concept of long-term doctrine. Unlike other industries, many biomedical companies do not make money or even have no income for a long time, but in the long run, this field is bound to produce world-class great companies.
However, due to the high previous gains, the overall performance of the pharmaceutical sector since the third quarter of this year is not eye-catching, with an increase of 8.93% only ranking 20th among Shenwan's 28 major industries. Observing the four pharmaceutical companies with heavy holdings of Hillhouse Capital at the end of the second quarter, although their share prices have risen in stages, only Jinyu Medicine has outperformed the industry average and the overall market average over the same period, up more than 25% since the beginning of July. Scan the QR code to open an account in 3 minutes to catch the skyrocketing stock market!
Responsible editor: Chen Zhijie